Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | HTR1D | P28221 | 1/20 | 0.65 |
| ▸ | HTR1B | P28222 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | HTR1E | P28566 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | HTR7 | P34969 | 1/20 | 0.65 |
| ▸ | HTR2B | P41595 | 1/20 | 0.65 |
| ▸ | HTR6 | P50406 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | TACR1 | P25103 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MPO | P05164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21292958 | 1.00 | HTR2A (0.70) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| Hydrochloric Acid SCHEMBL4632780 | 0.98 | HTR2A (0.68) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| SCHEMBL21292728 | 0.89 | HTR2A (0.56) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| SCHEMBL21292725 | 0.89 | HTR2A (0.56) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| SCHEMBL20424353 | 0.88 | HTR2A (0.67) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| Trifluoroacetic Acid SCHEMBL21292873 | 0.88 | KDM4E (0.56) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| Trifluoroacetic Acid SCHEMBL21292878 | 0.88 | KDM4E (0.56) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| SCHEMBL20430493 | 0.85 | HTR2A (0.71) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| Etryptamine SCHEMBL15281765 | 0.83 | HTR2A (1.00) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| Etryptamine SCHEMBL1172193 | 0.83 | HTR2A (1.00) | HTR2AADRB1HTR1AADRA2ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759075-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| CN-112041301-A | Compounds having iron death inducing activity and methods of use thereof | 费罗治疗公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | MOLECULAR SKIN THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | MOLECULAR SKIN THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | HTR2A 3134/4885ADRB1 4766/4885HTR1A 4288/4885 |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | AIFM2, GPX4, GPX1 | HTR2A 3059/4885ADRB1 4708/4885HTR1A 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.